Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
2
Neutral
10
Bullish
2
Investor Presentation
Q1 FY27
Bearish
2
Neutral
34
Bullish
10
Bearish
0
Neutral
24
Bullish
8
Healthcare Equipment & Supplies
Medical Equipment & Supplies
12,907 Cr
Low Risk
77.2
51.6
4.2
9.4
1,291.00
925.80
Sales CAGR
Profit CAGR
ROE
ROCE
Molbio Diagnostics Ltd (MOLBIO) is currently trading at 1,258.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Molbio Diagnostics Ltd operates in the its sector sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.
Over the past 52 weeks, Molbio Diagnostics Ltd has traded between a low of ₹925.80 and a high of ₹1,291.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Molbio Diagnostics Ltd has a market capitalization of approximately 12,907.46. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Molbio Diagnostics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 77.19 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 12,907.46 Cr, Molbio Diagnostics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Molbio Diagnostics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Molbio Diagnostics Ltd is 77.19. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The Board of Directors approved the unaudited standalone and consolidated results on September 5, 2026 for the quarter ended June 30, 2026.
Molbio Diagnostics has scheduled its earnings conference call for Sep 8, 2026 at 4:00 pm IST to discuss performance for the quarter ended Jun 30, 2026.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1730.20 | 17,538 Cr | 56.04 | 5.65 | 0.20 | 10.37 | 12.71 | 7.99 | ||
1120.05 | 12,907 Cr | 77.19 | 9.43 | 0.00 | 14.25 | 16.24 | 0.00 | ||
35.66 | 2,482 Cr | 83.25 | 5.08 | 0.13 | 8.06 | 10.61 | 3.65 | ||
325.80 | 1,735 Cr | 156.26 | 2.73 | 0.00 | 2.26 | 4.09 | 0.94 | ||
624.05 | 1,456 Cr | 26.12 | 2.98 | 0.00 | 22.63 | 19.42 | 9.98 | ||
198.75 | 1,095 Cr | 38.19 | 4.50 | 0.00 | 13.74 | 14.03 | 9.76 | ||
404.40 | 701 Cr | 62.18 | 4.03 | 0.00 | 5.88 | 7.65 | 5.02 | ||
| Median: 7 Co. | — | 404.40 | 1,735 Cr | 62.18 | 4.50 | 0.00 | 10.37 | 12.71 | 5.02 |
Regulatory/Compliance Filing
Molbio Diagnostics Ltd notifies change of CIN from U33125GA2000PLC002909 to L33125GA2000PLC002909 after listing on NSE and BSE on 2026-08-17; MCA status updated from 'Unlisted' to 'Listed'.
Earnings Call/Transcript
Molbio Diagnostics Ltd has posted the audio recording of the earnings call held on 2026-09-08 for the quarter ended June 30, 2026 on its website (https://www.molbiodiagnostics.com).
Financial Results
Molbio Diagnostics Ltd published newspaper advertisements of its unaudited financial results for the quarter ended 30-06-2026 in Financial Express and Tarun Bharat on 07-09-2026; summary financials included.
Financial Results
Molbio Diagnostics Ltd reported Q1 FY27 unaudited results: Total Income ₹411.48 Cr, EBITDA ₹103.68 Cr (25.2%), PAT ₹52.74 Cr; growth driven by Truenat test-kit volumes and post-listing deployment of proceeds.
Financial Results
Molbio Diagnostics approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with limited review reports; Board also authorised KMPs to determine materiality of events.
Financial Results
Molbio Diagnostics Ltd: Board approved unaudited standalone and consolidated financial results for quarter ended June 30, 2026 (limited review completed) and authorized KMPs to determine materiality of events.
